The crossover design makes interpreting raw trial results tricky. When the placebo group receives the active compound partway through and some of the treatment group shifts to placebo, the final data reflects mixed effects rather than clean long-term outcomes. The personal six-month result in this thread is real-world data that a crossover design can't fully capture - individual outcomes on the timeline they actually happen on tell a different story than the trial endpoints.